Review on Relationship between Hypertension and Diabetes with their Medications
DOI:
https://doi.org/10.22270/ajprd.v13i1.1505Abstract
Hypertension and diabetes are two very common chronic conditions in the modern world, and they are closely related. Hypertension is a condition in which blood pressure is consistently high, and diabetes is a condition in which blood sugar levels are abnormally high. Both conditions increase the risk of cardiovascular disease, kidney disease, and many other complications. Studies have shown that many people with high blood pressure also have diabetes, and vice versa.In conclusion, hypertension and diabetes are interrelated conditions that can cause serious health problems for many people in the modern world. People with diabetes are more likely than the general population to develop high blood pressure because diabetes can cause damage to blood vessels or trigger an inflammatory response within the blood vessels, which can lead to stiffness of the blood vessels.Conversely, high blood pressure makes diabetes worse. When hypertension persists, the burden on the blood vessels continues to increase, putting the kidneys and heart of diabetics at greater risk.The bottom line is that these two conditions end up interacting with each other and promoting different complications.This approach will go a long way toward preventing the development of hypertension and diabetes and leading a healthy life.
Downloads
References
Michael J Cryer, Tariq Horani, Donald J DiPette. Diabetes and Hypertension: A Comparative Review of Current Guidelines J Clin Hypertens (Greenwich). 2016 Feb; 18(2):95-100.
M Epstein, J R Sowers. Diabetes mellitus and hypertension. Hypertension. 1992 May; 19(5):403-18.
Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis, prevention and treatment.
Clin Exp Hypertens. 2004 Oct-Nov; 26(7-8):621-8.
Litwin M, Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. PediatrNephrol. 2021 Apr;36(4):825-837.
Seedat YK. Nutritional aspects of hypertension. S Afr Med J. 1989 Feb 18; 75(4):175-7.
Xue B, Zhang Y, Johnson AK. Interactions of the Brain Renin-Angiotensin-System (RAS) and Inflammation in the Sensitization of Hypertension. Front Neurosci. 2020 Jul 15; 14:650.
Stump M, Mukohda M, Hu C, Sigmund CD. PPARgamma Regulation in Hypertension and Metabolic Syndrome. CurrHypertens Rep. 2015 Dec; 17(12):89.
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52.
Laffin LJ, BakrisGL.. Hypertension and new treatment approaches targeting the sympathetic nervous system. CurrOpinPharmacol. 2015 Apr; 21:20-4.
Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017; 956:511-540.
Herrmann SM, Textor SC. Renovascular Hypertension. Endocrinol Metab Clin North Am. 2019 Dec;48(4):765-778.
Ferreira-Campos L, Gabrielli L, Almeida MDCC, Aquino EML, Matos SMA, Griep RH, Aras R. Hormone therapy and Hypertension in Postmenopausal Women: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Arq Bras Cardiol. 2022 May; 118(5):905-913.
Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:511-540.
Márquez A, Martín J. Genetic overlap between type 1 diabetes and other autoimmune diseases.SeminImmunopathol. 2022 Jan; 44(1):81-97.
Xiao J, Li J, Cai L, Chakrabarti S, Li X. Cytokines and diabetes research. J Diabetes Res. 2014;2014:920613. doi: 10.1155/2014/920613. Epub 2014 Jan 16.
Alam F, Islam MA, Khalil MI, Gan SH. Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches. Curr Pharm Des. 2016;22(20):3034-49.
Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236.
Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, Fan K, Liu J, Zhu Y, Wang Z, Zhang Y, Chen L. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023 Sep 28;29(1):132. doi: 10.1186/s10020-023-00721-7.
Yousri NA, Suhre K, Yassin E, Al-Shakaki A, Robay A, Elshafei M, Chidiac O, Hunt SC, Crystal RG, Fakhro KA. Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia. Diabetes. 2022 Feb 1;71(2):184-205. doi: 10.2337/db21-0490.
Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules. 2022 Apr 4;12(4):542. doi: 10.3390/biom12040542.
Belosludtsev KN, Belosludtseva NV, Dubinin MV. Diabetes Mellitus, Mitochondrial Dysfunction and Ca(2+)-Dependent Permeability Transition Pore. Int J Mol Sci. 2020 Sep 8;21(18):6559.
Rendra E, Riabov V, Mossel DM, Sevastyanova T, Harmsen MC, Kzhyshkowska J. Reactive oxygen species (ROS) in macrophage activation and function in diabetes. Immunobiology. 2019 Mar;224(2):242-253.
Lardaro A, Quarta L, Pagnotta S, Sodero G, Mariani S, Del Ben M, Desideri G, Ettorre E, Baratta F. Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline. Biomedicines. 2024 Aug 3;12(8):1750.
Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021 May;26(3):623-642. doi: 10.1007/s10741-020-10038-w. Epub 2020 Dec 4.
Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. Expert OpinPharmacother. 2023 Sep-Dec;24(18):2187-2198.
Huang K, Luo X, Liao B, Li G, Feng. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. J. Cardiovasc Diabetol. 2023 Apr 13;22(1):86.
Cook AK, Behrend E. SGLT2 inhibitor use in the management of feline diabetes mellitus.
J Vet PharmacolTher. 2025 Jan;48 Suppl 1(Suppl 1):19-30.
Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019 Dec;7(12):949-958.
Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, Velliou ML, Barbetseas JD. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). Am J Cardiovasc Drugs. 2021 Mar;21(2):123-137.
Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs. 2006;66(9):1169-77.
Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014 Aug 22;2014(8):CD009096. doi: 10.1002/14651858.CD009096.pub2.
Omboni S, Volpe M. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. Adv Ther. 2019 Feb;36(2):278-297.
Heise T. Novel Drugs for Diabetes Therapy. Handb Exp Pharmacol. 2022;274:415-438.
Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014 Aug;28(8):463-8.
Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020 Dec;17(12):761-772.
Cunha TDS, Gomes SA, Heilberg IP. Thiazide and thiazide-like diuretics in nephrolithiasis. J Bras Nefrol. 2021 Jan-Mar;43(1):103-109.
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410.
Jiaying Zhu, Ning Chen, Muke Zhou, Jian Guo, Cairong Zhu, Jie Zhou, Mengmeng Ma, Li He. Calcium channel blockers versus other classes of drugs for hypertension Cochrane Database Syst Rev. 2022 Jan 9;1(1):CD003654.
Barnett AH. Diabetes and hypertension. Br Med Bull. 1994 Apr;50(2):397-407.
Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 Jul 11;396(10244):121-128.
Yamal JM, Martinez J, Osani MC, Du XL, Simpson LM, Davis BR. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 Dec 1;6(12):e2344998.
Gouni-Berthold I, Hanssen R, Ravarani L, Berthold HK. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des. 2017;23(31):4573-4582.
Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 Feb 6;149(6):450-462.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Cheolin Park, Jaeeun Jung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.